Pentixapharm Holding AG (XTER:PTP) YoY EPS Growth: 16.28% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:PTP Pentixapharm Holding AG XTER:PTP
20 GF Score
Price €1.85
! 1 Warning Sign
View Full Analysis

What is Pentixapharm Holding AG YoY EPS Growth?

Pentixapharm Holding AG XTER:PTP -0.27% 20 YoY EPS Growth is 16.28% as of Jun. 2026. GuruFocus rates XTER:PTP with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Pentixapharm Holding AG's YoY EPS Growth for the quarter that ended in Jun. 2026 was 16.28%.

Pentixapharm Holding AG's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was €-0.14.

Pentixapharm Holding AG YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG YoY EPS Growth Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
0.00 20.83 -288.16 -68.81 -28.92

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17,100.00 94.21 68.78 18.30 16.28
XTER:PTP
20GF Score
Pentixapharm Holding AG XTER:PTP
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Pentixapharm Holding AG's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.642--0.498)/ | -0.498 |
=-28.92 %

Pentixapharm Holding AG's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.144--0.172)/ | -0.172 |
=16.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 16.28% mean?
Pentixapharm Holding AG (XTER:PTP) has a YoY EPS Growth of 16.28% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's YoY EPS Growth too high?
Pentixapharm Holding AG's current YoY EPS Growth is 16.28%. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's YoY EPS Growth compare to VRTX and REGN?
Pentixapharm Holding AG's YoY EPS Growth of 16.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current YoY EPS Growth is 16.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current YoY EPS Growth of 16.28%. The current YoY EPS Growth is 16.28%. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current YoY EPS Growth is 16.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for XTER:PTP

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.85
Price